Study on biomarkers of acteoside in treating puromycin aminonucleoside nephropathy in young rats based on non-targeted urine metabolomics technology

• Published in: Zhongguo zhongyao zazhi Vol. 48; no. 21; p. 5898
• Main Authors: Wang, Meng-Xiao, Luo, Ke-Ke, Gao, Wen-Ya, Tian, Meng-Yao, Zhao, Hai-Yu, Si, Nan, Bian, Bao-Lin, Wei, Xiao-Lu, Wang, Hong-Jie, Zhou, Yan-Yan
• Format: Journal Article
• Language: Chinese
• Published: China 01.11.2023
• Subjects: acteoside; purinomycin aminonucleoside nephropathy; biomarker; non-targeted urine metabonomics
• ISSN: 1001-5302
• DOI: 10.19540/j.cnki.cjcmm.20230707.406

This study aims to reveal the endogenous metabolic characteristics of acteoside in the young rat model of purinomycin aminonucleoside nephropathy(PAN) by non-targeted urine metabolomics and decipher the potential mechanism of action. Biochemical indicators in the urine of rats from each group were determined by an automatic biochemical analyzer. The potential biomarkers and related core metabolic pathways were identified by ultra-high performance liquid chromatography coupled with linear ion trap-Orbitrap mass spectrometry(UHPLC-LTQ-Orbitrap MS) combined with principal component analysis(PCA) and orthogonal partial least squares-discriminant analysis(OPLS-DA). MetaboAnalyst 5.0 was used to establish the receiver operating characteristic(ROC) curve for evaluating the clinical diagnostic performance of core metabolites. The results showed that acteoside significantly decreased urinary protein-to-creatinine ratio in PAN young rats. A total of 17 differential metabolites were screened out by non-targeted urine me